OS was significantly shorter in patients with high MYL9 expression in the moderate/well tumor differentiation subgroup (n = 99, p = 0.002; Fig 4C), T3+T4 subgroup (n = 103, p = 0.001; Fig 4D), and in patients without lymph node metastasis (n = 67, p = 0.009; Fig 4E). This evidence concerns the gene MYL9 and metastatic malignant neoplasm in the lymph nodes.